You are here: Industry Insights > Humira

News List

Top 10 all-star drugs in 2024: Humira's captain, but who else makes the roster? fiercepharma
August 18, 2019
Heart drug Lipitor is the biggest-selling drug of all time. Perhaps no surprise to dedicated pharma-watchers, who know the statin med still racks up blockbuster-level sales despite years of generic competition.
FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira drugs
July 25, 2019
Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Hadlima (adalimumab-bwwd)...
AbbVie keeps May TV focus on Humira, while Gilead spends big on HIV drugs fiercepharma
June 28, 2019
Will AbbVie back off Humira advertising now that it’s announced it will buy Allergan? Maybe. But for now, the Illinois drugmaker is showing no signs of slowing its long-running robust TV ad push for the world's best-selling drug.
AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan expressbpd
June 27, 2019
AbbVie has long been under pressure to diversify its portfolio and its shares have lost more than a third of their value since January 2018 over concerns about Humira Drugmaker AbbVie said that it would acquire Allergan for about $63 billion ...
Patent litigation for adalimumab resolved in the US europeanpharmaceuticalreview
May 29, 2019
AbbVie has announced that it has resolved its US HUMIRA (adalimumab) litigation with Boehringer Ingelheim.
Boehringer buckles in AbbVie patent fight, saving Humira from biosims until 2023 fiercepharma
May 15, 2019
Boehringer Ingelheim fought hard against AbbVie’s so-called “patent thicket” surrounding the world’s bestselling med, Humira. But in the end, the German company ended up settling, just like its fellow biosimilar makers.
AbbVie raises annual earnings guidance despite drop in Q1 sales, profit on biosimilar hit to Humira firstwordpharma
April 26, 2019
"We are off to another excellent start, including first quarter sales and earnings above expectations," remarked CEO Richard Gonzalez ...
Physician View snap poll: Gastroenterologists assess the impact of Takeda's new head-to-head data for Entyvio in ulcerative colitis firstwordpharma
April 04, 2019
Takeda recently unveiled data showing Entyvio was superior to AbbVie's Humira at achieving clinical remission in moderate-to-severe ulcerative colitis patients at 52 weeks.
Takeda’s Entyvio achieves superior remission than Humira in ulcerative colitis pharmaceutical-technology
March 13, 2019
Takeda has announced results from Phase IIIb head-to-head study of two biologic therapies, Entyvio (vedolizumab) and adalimumab, the generic of AbbVie’s Humira, in which Entyvio achieved statistically significant clinical remission in patients with modera
Takeda’s Entyvio outperforms AbbVie’s Humira in GI trial March 12, 2019
Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis.

Previous page 1 2 3 4 5 6 7 Next page